Sjogren's syndrome is the most common of the autoimmune diseases, affecting 2-4 million individuals. Most patients are female, and the average age of onset is 50. Dry mouth is one of the cardinal symptoms, along with chronic mouth sores, tooth decay, and salivary gland inflammation. Little is known about the epidemiology of Sjogren's syndrome, including the specific prevalence, risk factors, natural history, or comorbidities. In order to obtain preliminary descriptive information, a 28-item questionnaire focused on onset and diagnosis, current treatment, symptomatology and comorbid illness, and effects on quality of life was mailed to the members of the Sjogren's Syndrome Foundation. A sample of ~3400 individuals (50% of the national membership) returned the questionnaire. The sample was predominantly female (95%), older (median age 62), and married (71%). Ten percent were diagnosed with Sjogren's by a dentist, and only 56% had seen a dentist in the past year. Although 88% reported that dry mouth was one of their most troubling symptoms, only 28% used a saliva substitute and 17% were taking Pilocarpine. Forty percent rated their health as fair or poor, and 36% believed that their health interfered with their daily life most of almost all of the time. Women reporting more oral symptoms (problems talking, tooth decay, and mouth sores) were more likely to report more comorbid conditions, such as arthritis and depression. The implications of the findings for future research in representative samples of people with Sjogren's syndrome are discussed.
Learning Objectives: Describe epidemiology of Sjogren's syndrome Show extent of comorbidity and impact on quality of life
Keywords: Chronic Illness, Quality of Life
Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: Sjogren's Syndrome Foundation
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.